Status:
RECRUITING
Rapid Analysis of Infections by Spectrometry of Exhaled Breath
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Respiratory Tract Infections
Hematologic Diseases
Eligibility:
All Genders
18+ years
Brief Summary
To quantify the diagnostic, prognostic and therapeutic value of spectrometric analysis of exhaled breath from hematological patients with respiratory infection.
Eligibility Criteria
Inclusion
- Age ≥ 18y at start of study
- One of the following diagnoses:
- De novo, refractory or relapsed AML/MDS receiving intensive chemotherapy
- De novo, refractory or relapsed ALL/T-lymphoblastic lymphoma receiving intensive chemotherapy
- Aplastic anemia requiring ATG therapy
- Any patient admitted for either autologous hematopoietic stem cell transplantation. Transplantation may not have been performed at time of enrolment.
- Any patient admitted with allogeneic hematopoietic stem cell transplantation within the last year, or planned during this admission.
- Written informed consent obtained from the patient
Exclusion
- Hematological disease beyond the specified inclusion criteria
- Signs of active respiratory infection
- If previously enrolled: incomplete clearance of all signs of respiratory infection (both clinically, microbiologically and radiologically).
Key Trial Info
Start Date :
June 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT03299608
Start Date
June 21 2019
End Date
September 1 2025
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Leuven
Leuven, Belgium, 3000